Vir Biotechnology Inc Dossier - Source-backed chat

Vir Biotechnology Inc

VIRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.38

Intrinsic Value $9.42median of 2 methodsbased on filings through 30 Jun 2026

Market Price $11.18Price as of 30 Sep 2026

OvervaluedIntrinsic value is 16% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1.9B

Enterprise Value $1.6B

Shares Outstanding 158.2M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Vir Biotechnology is undergoing a strategic transformation, pivoting from its legacy infectious disease focus toward a high-potential oncology pipeline while advancing its registrational-stage chronic hepatitis delta (CHD) program. The company's investment thesis is anchored by two major validation points: a landmark global strategic collaboration with Astellas Pharma for its PSMA-targeted T-cell engager (TCE) VIR-5500, and highly promising Phase 2 SOLSTICE data for its CHD combination regimen (tobevibart and elebsiran). Backed by a robust cash runway extending into the second half of 2028, Vir is well-positioned to navigate upcoming high-impact clinical catalysts, including Phase 3 ECLIPSE 1 data in Q4 2026 and Phase 1 oncology readouts in H2 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$15.00

Mean target$21.00

High · most bullish analyst$30.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$15.0015%

The ECLIPSE 1 Phase 3 trial fails to replicate the high viral suppression rates seen in Phase 2, or reveals unexpected safety concerns, severely damaging the commercial outlook for the CHD program. In oncology, VIR-5500 or VIR-5818 clinical readouts show limited durability of response or increased toxicities (such as high-grade CRS) during dose expansion, undermining the perceived value of the PRO-XTEN masking platform. Elevated R&D expenses accelerate the cash burn rate, forcing the company to seek dilutive financing earlier than expected.

Base CaseCentral scenario

$21.0060%

Matches the consensus mean

The ECLIPSE 1 Phase 3 trial meets its primary endpoints in Q4 2026, confirming the high efficacy (undetectable HDV RNA) and favorable tolerability observed in the Phase 2 SOLSTICE trial. This supports regulatory filings in the US and Europe in 2027. VIR-5500 successfully advances through its Phase 1 dose-expansion cohorts in collaboration with Astellas, maintaining a manageable safety profile with limited cytokine release syndrome (CRS) and showing competitive anti-tumor activity. The company's cash runway remains secure into 2028, allowing disciplined execution across both the CHD and oncology portfolios.

Bull CaseUpside scenario

$30.0025%

The combination of tobevibart and elebsiran delivers outstanding Phase 3 results in the ECLIPSE 1 trial in Q4 2026, establishing a best-in-class profile for chronic hepatitis delta with high rates of undetectable HDV RNA and convenient monthly subcutaneous dosing. Simultaneously, VIR-5500 demonstrates deep, durable responses in Phase 1 expansion cohorts, accelerating its path to pivotal Phase 3 trials in 2027. The PRO-XTEN platform is further validated by positive VIR-5818 HER2 data in H2 2026, triggering additional pharmaceutical partnerships and upfront payments, significantly expanding the company's valuation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong validation of the oncology pipeline through the $1.7 billion Astellas collaboration for VIR-5500, which provided $315 million in upfront cash and equity investments in Q2 2026.
Highly encouraging Phase 2 SOLSTICE data in chronic hepatitis delta, showing that the combination of tobevibart and elebsiran achieved undetectable HDV RNA in 88% of participants at Week 96.
Robust balance sheet with $809.3 million in cash and investments as of March 31, 2026, which excludes the $315 million from the Astellas deal, extending the operational runway into the second half of 2028.
Proprietary PRO-XTEN dual-masking technology platform designed to improve the therapeutic index of T-cell engagers in solid tumors by limiting systemic toxicity like cytokine release syndrome.

Key Investment Risks

Clinical development risk, as the company's valuation is heavily dependent on upcoming Phase 3 readouts for the CHD program and Phase 1/2 readouts for the oncology pipeline.
High operational cash burn rate driven by expensive late-stage clinical trials, which could pressure the balance sheet if clinical milestones are delayed.
Intense competition in the oncology space, particularly for PSMA-targeted therapies in metastatic castration-resistant prostate cancer.
Regulatory hurdles and potential delays in obtaining approvals from the FDA and EMA for its lead candidates.

Thesis Invalidation Triggers

Failure of the ECLIPSE 1 Phase 3 trial to meet its primary efficacy or safety endpoints in Q4 2026.
Severe safety signals, such as high-grade cytokine release syndrome or dose-limiting toxicities, emerging in the VIR-5500 or VIR-5818 clinical trials.
Termination or material negative restructuring of the strategic collaboration with Astellas Pharma.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.